High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20204-20214

  Wang, Bo ^a   Liu, Hao ^a   Dong, Xiaoliang ^a   Wu, Shaoxu ^a   Zeng, Hong ^a   Liu, Zhuowei ^a   Wan, Di ^a   Dong, Wen ^a   He, Wang ^a   Chen, Xu ^a   Zheng, Limin ^b   Huang, Jian ^a   Lin, Tianxin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CD169; CD204; Tumor infiltrating macrophages; Urothelial cell carcinoma of the bladder (UCB)

Indexed keywords

CD68 ANTIGEN; PROTEIN CD204; SCAVENGER RECEPTOR A; SIALOADHESIN; TUMOR MARKER; UNCLASSIFIED DRUG; MSR1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CELL DENSITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; STROMA CELL; TISSUE DISTRIBUTION; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; VERY ELDERLY; BIOSYNTHESIS; BLADDER TUMOR; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; MACROPHAGE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; SCAVENGER RECEPTORS, CLASS A; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84940192893     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3887     Document Type: Article

References (32)

1. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010; 60:244-272.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64:639-653.
3. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol. 2014; 11:153-162.
4. Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer. 2004; 91:607-612.
5. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4:839-849.
6. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21:309-322.
7. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity. 2014; 41:14-20.
8. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4:71-78.
9. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141:39-51.
10. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013; 229:176-185.
11. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66:605-612.
12. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol. 2011; 55:861-867.
13. Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, Lin Z, Xu J. Prognostic value of diametrically polarized tumorassociated macrophages in renal cell carcinoma. Ann Surg Oncol. 2014; 21:3142-3150.
14. Bowdish DM, Gordon S. Conserved domains of the class A scavenger receptors: evolution and function. Immunol Rev. 2009; 227:19-31.
15. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, Takeya M. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011; 102:1424-1431.
16. Kaku Y, Imaoka H, Morimatsu Y, Komohara Y, Ohnishi K, Oda H, Takenaka S, Matsuoka M, Kawayama T, Takeya M, Hoshino T. Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease. PLoS One. 2014; 9:e87400.
17. Sugimoto M, Mitsunaga S, Yoshikawa K, Kato Y, Gotohda N, Takahashi S, Konishi M, Ikeda M, Kojima M, Ochiai A, Kaneko H. Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. Eur J Cancer. 2014; 50:1900-1908.
18. O'Neill AS, van den Berg TK, Mullen GE. Sialoadhesin-a macrophage-restricted marker of immunoregulation and inflammation. Immunology. 2013; 138:198-207.
19. Klaas M, Crocker PR. Sialoadhesin in recognition of self and non-self. Semin Immunopathol. 2012; 34:353-364.
20. Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, Tanaka M. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011; 34:85-95.
21. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012; 125:5591-5596.
22. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13.
23. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000; 7:263-269.
24. Sjodahl G, Lovgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, Mansson W, Ferno M, Leandersson K, Lindgren D, Liedberg F, Hoglund M. Infiltration of CD3 and CD68 cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol. 2014; 32:791-797.
25. Wu Y, Zheng L. Dynamic education of macrophages in different areas of human tumors. Cancer Microenviron. 2012; 5:195-201.
26. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960-1964.
27. Neyen C, Pluddemann A, Mukhopadhyay S, Maniati E, Bossard M, Gordon S, Hagemann T. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol. 2013; 190:3798-3805.
28. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 206:1327-1337.
29. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009; 33:118-126.
30. Huang J, Lin T, Liu H, Xu K, Zhang C, Jiang C, Huang H, Yao Y, Guo Z, Xie W. Laparoscopic radical cystectomy with orthotopic ileal neobladder for bladder cancer: oncologic results of 171 cases with a median 3-year follow-up. Eur Urol. 2010; 58:442-449.
31. Liu J, Cai M, Chen J, Liao Y, Mai S, Li Y, Huang X, Liu Y, Zhang J, Kung H, Zeng Y, Zhou F, Xie D. alpha4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. Eur J Cancer. 2014; 50:840-851.
32. Wang B, Shaoxu W, Zeng H, Liu Z, Dong W, Wang H, Chen X, Dong X, Zheng L, Lin T, Huang J. CD103 tumorinfiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol. 2015; pii: S0022-5347:03268-1.